# Telix to Host Capital Markets Day in Melbourne on November 4, 2026

- Link: https://www.thailand-business-news.com/pr-news/telix-to-host-capital-markets-day-in-melbourne-on-november-4-2026
- Published: 2026-10-09T03:00:00+07:00
- Author: PR Newswire

|   |

MELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ — Telix Pharmaceuticals
Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that it will host a Capital
Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.
m. to 12:30 p.m. (AEDT).

Institutional investors and analysts are invited to attend the in-person event, 
which will provide an update on Telix’s commercial portfolio, late-stage pipeline
and strategic growth opportunities. Members of the Telix leadership team will present
at the event, which will also feature key opinion leaders who will provide their
perspectives on Telix’s theranostic programs.

Advance registration is required for in-person attendance. To register your interest
please contact: [charlene.jaw@telixpharma.com](https://www.thailand-business-news.com/pr-news/charlene.jaw@telixpharma.com)
or [annie.kasparian@telixpharma.com](https://www.thailand-business-news.com/pr-news/annie.kasparian@telixpharma.com).

The event will be webcast live and available via the Investor Relations section 
of the Telix website.

**About Telix Pharmaceuticals Limited **

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical
company, advancing targeted theranostics to improve outcomes for people with cancer
across the patient journey. Theranostics pairs a precision diagnostic with a targeted
therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its precision diagnostics portfolio:
Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially
available in 22 countries including the U.S., and Gozellix® (kit for the preparation
of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration(
FDA) for prostate imaging, and Pixclara® (floretyrosine F 18) approved by the FDA
for glioma imaging. The Company’s late-stage therapeutic pipeline includes three
investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (^(177)Lu)
rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan ^(131)I) in recurrent
glioblastoma, and TLX250-Tx (lutetium (^(177)Lu) girentuximab tetraxetan) in kidney
cancer, additionally complemented by a deep pipeline of next generation candidates.

Telix is headquartered in Melbourne, Australia, with operations across North America,
Europe, Latin America and Asia-Pacific. For more information, visit [www.telixpharma.com](http://www.telixpharma.com/)
or follow Telix on [LinkedIn](https://www.linkedin.com/company/telixpharma/),[X](https://x.com/TelixPharma)
and [Facebook](https://www.facebook.com/TelixPharma).

  |

**Investor Relations**

Annie Kasparian 
[annie.kasparian@telixpharma.com](https://www.thailand-business-news.com/pr-news/annie.kasparian@telixpharma.com)

  |

Charlene Jaw
[charlene.jaw@telixpharma.com](https://www.thailand-business-news.com/pr-news/charlene.jaw@telixpharma.com)

  |

Legal Notices

_Cautionary Statement Regarding Forward-Looking Statements._  
 

_You should read this announcement together with our risk factors, as disclosed 
in our most recently filed reports with the Australian Securities Exchange (ASX),
U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form
20-F filed with the SEC, or on our website._

_The information contained in this announcement is not intended to be an offer for
subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals
Limited (Telix) in any jurisdiction, including the United States. The information
and opinions contained in this announcement are subject to change without notification.
 To the maximum extent permitted by law, Telix disclaims any obligation or undertaking
to update or revise any information or opinions contained in this announcement, 
including any forward-looking statements (as referred to below), whether as a result
of new information, future developments, a change in expectations or assumptions,
or otherwise. No representation or warranty, express or implied, is made in relation
to the accuracy or completeness of the information contained or opinions expressed
in the course of this announcement._

_This announcement may contain forward-looking statements, including within the 
meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate
to anticipated future events, financial performance, plans, strategies or business
developments. Forward-looking statements can generally be identified by the use 
of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe","
outlook", "forecast" and "guidance", or the negative of these words or other similar
terms or expressions. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to differ materially from any future results, levels
of activity, performance or achievements expressed or implied by these forward-looking
statements. Forward-looking statements are based on Telix’s good-faith assumptions
as to the financial, market, regulatory and other risks and considerations that 
exist and affect Telix’s business and operations in the future and there can be 
no assurance that any of the assumptions will prove to be correct. In the context
of Telix’s business, forward-looking statements may include, but are not limited
to, statements about: the initiation, timing, progress, completion and results of
Telix’s preclinical and clinical trials, and Telix’s research and development programs;
Telix’s ability to advance product candidates into, enroll and successfully complete,
clinical studies, including multi-national clinical trials; the timing or likelihood
of regulatory filings and approvals for Telix’s product candidates, manufacturing
activities and product marketing activities; Telix’s sales, marketing and distribution
and manufacturing capabilities and strategies; the commercialization of Telix’s 
product candidates, if or when they have been approved; Telix’s ability to obtain
an adequate supply of raw materials at reasonable costs for its products and product
candidates; estimates of Telix’s expenses, future revenues and capital requirements;
Telix’s financial performance; developments relating to Telix’s competitors and 
industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic
conditions on Telix’s business, including as a result of war or other geopolitical
conflicts; and the pricing and reimbursement of Telix’s product candidates, if and
after they have been approved. Telix’s actual results, performance or achievements
may be materially different from those which may be expressed or implied by such
statements, and the differences may be adverse. Accordingly, you should not place
undue reliance on these forward-looking statements._

_Trademarks and Trade Names. All trademarks and trade names referenced in this press
release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable,
the property of their respective owners. For convenience, trademarks and trade names
may appear without the ® or ™ symbols. Such omissions are not intended to indicate
any waiver of rights by Telix or the respective owners. Trademark registration status
may vary from country to country. Telix does not intend the use or display of any
third-party trademarks or trade names to imply any affiliation with, endorsement
by, or sponsorship from those third parties._

_©2026 Telix Pharmaceuticals Limited. All rights reserved._

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Telix to Host Capital Markets Day in Melbourne on November 4, 2026 ](http://www.prnasia.com/story/archive/5066888_AE66888_0?rand=184833)